AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VALN · NASDAQ · Biotechnology

Valneva (ADR) (VALN)

Develops, manufactures, and sells travel vaccines alongside infectious-disease vaccine programs.

$6.47

vs last close−0.12 (−1.85%)

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	43	48	37	43	52	60	56	55	34	54	35	40
Cost of revenue	24	30	25	27	29	31	26	27	27	41	30	39
Gross profit	19	18	12	17	23	29	30	28	6	13	5	2
	45	46	−66	41	37	53	37	40	49	45	32	33
Research & development	19	20	15	19	22	29	17	20	31	29	17	17
	30	31	26	26	25	31	22	23	21	19	17	16
Selling & marketing	16	17	13	14	14	19	12	11	9	10	8	7
General & administrative	14	15	13	13	11	12	10	11	12	9	9	8
Other expenses	−3	−5	−107	−4	−10	−7	−2	−3	−4	−3	−2	0
Operating income	−25	−28	78	−25	−14	−24	−7	−12	−42	−32	−27	−31
	−11	−4	−11	−4	−1	−13	−2	−1	−7	−27	−9	−5
Interest income	0	1	0	1	1	1	1	1	1	0	1	1
Interest expense	4	12	8	6	7	7	7	6	6	28	6	6
Other non-operating income	7	−9	3	−2	−6	6	0	−5	0	−1	0	0
Income before tax	−36	−32	67	−29	−15	−37	−9	−13	−50	−58	−36	−37
Income tax expense	3	4	0	0	−4	5	2	0	1	−1	1	−1
Net income from continuing operations	−39	−37	67	−28	−11	−42	−11	−13	−51	−57	−37	−36
Net income	−39	−37	67	−28	−11	−42	−11	−13	−51	−57	−37	−36
EPS, basic	−$0.57	−$0.52	$0.96	−$0.43	−$0.15	−$0.59	−$0.14	−$0.17	−$0.59	−$0.66	−$0.43	−$0.39
EPS, diluted	−$0.57	−$0.52	$0.96	−$0.43	−$0.15	−$0.59	−$0.14	−$0.17	−$0.59	−$0.66	−$0.43	−$0.39
Weighted average shares, basic	69	69	69	66	70	70	77	77	86	87	86	95
Weighted average shares, diluted	69	69	69	66	70	70	77	77	86	87	86	95
EBITDA	−27	−16	75	−12	−3	−29	−3	−7	−36	−23	−22	−26
Depreciation & amortization	5	3	0	11	6	0	4	0	6	7	5	5
EBIT	−32	−20	75	−23	−8	−30	−7	−7	−43	−30	−27	−31